Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-LY trial of dabigatran versus warfarin in non-valvular atrial fibrillation
2005-003894-26Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran and warfarin in Atrial fibrillation (AFib) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of all stroke or systemic embolism. Started Oct 2005; status: completed.
02
Drugs
dabigatranwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2005-003894-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003894-26.